Overview
Miriam Iezza practices practicing medicine in Bologna, Italy.
Her clinical expertise encompasses Chronic Myelogenous Leukemia (CML), Multiple Myeloma, and Leukemia.
She is actively involved in clinical research, co-authoring 14 peer reviewed articles.
Gender
Locations
Clinical Research
Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.
Frequently Asked Questions about Miriam Iezza
Is Miriam Iezza a top-rated expert for Chronic Myelogenous Leukemia (CML)?
MediFind is an objective health platform that identifies experts based on real-world data. Miriam Iezza is classified as an Experienced expert for Chronic Myelogenous Leukemia (CML), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.
Does Miriam Iezza participate in research or clinical trials?
Yes. Miriam Iezza has published 14 articles and abstracts on conditions like Chronic Myelogenous Leukemia (CML). You can view a list of Miriam Iezza's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.
Areas of Expertise
MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.
Learn more about MediFind’s expert tiers
- Experienced
- Chronic Myelogenous Leukemia (CML)Ms. Iezza isExperienced. Learn about Chronic Myelogenous Leukemia (CML).
- LeukemiaMs. Iezza isExperienced. Learn about Leukemia.
- Multiple MyelomaMs. Iezza isExperienced. Learn about Multiple Myeloma.